Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this
trial is to evaluate the safety of escalating single doses of rFXIII (recombinant factor
XIII, catridecacog) administered following first time myocardial revascularization requiring
cardiopulmonary bypass (CPB).